Skip to search formSkip to main contentSkip to account menu

MK 996

Known as: Benzamide, N-((4'-((2-ethyl-5,7-dimethyl-3H-imidazo(4,5-b)pyridin-3-yl)methyl)(1,1'-biphenyl)-2-yl)sulfonyl)-, MK-996 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ImidazolesPyridines
L 159282

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Investigation of the polymorphism of the angiotensin II antagonist agent MK-996.
The polymorphism of the angiotensin II antagonist agent MK-996 was studied, with particular emphasis on crystal form stability… 
1998
1998
Investigation of angiotensin II/AT1 receptors with carbon-11-L-159,884: a selective AT1 antagonist.
UNLABELLED Antagonists of the angiotensin II AT1 receptor subtype have been recently introduced for treatment of arterial… 
1995
1995
In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
1995
1995
C24 - Efficacy and tolerability of multiple doses of MK-996, an angiotensin II (AII) receptor antagonist, compared to enalapril and to placebo in mild to moderate hypertensive patients
1994
1994
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
1994
1994
Carbon-11 labeling of nonpeptide angiotensin-II antogonists: MK-996 and analogs
Our goal was to develop a tracer that can be used for imaging of angiotensin-II (ANG-II), AT{sub 1} receptors in vivo via PET. MK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)